Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1106
Title: Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.
Author: Neoh, Chin Fen
Senol, Esin
Kara, Ates
Dinleyici, Ener Cagri
Turner, Stuart J.
Kong, David C.M.
Issue Date: 2017
Publication Title: Mycoses
Volume: 60
Issue: 11
Start Page: 714
End Page: 722
Abstract: Anidulafungin has been shown to be non-inferior to, and possibly more efficacious, than fluconazole in treating patients with invasive candidiasis (IC). This study aimed to determine the cost-effectiveness of anidulafungin vs fluconazole for treatment of IC in the Turkish setting. A decision analytic model was constructed to depict downstream economic consequences of using anidulafungin or fluconazole for treatment of IC in the Turkish hospitals. Transition probabilities (ie treatment success, observed or indeterminate treatment failures) were obtained from a published randomised clinical trial. Cost inputs were from the latest Turkish resources. Data not available in the literature were estimated by expert panels. Sensitivity analyses were performed to assess the robustness of the model outcome. While anidulafungin [TL 17 171 (USD 4589)] incurred a higher total cost than fluconazole [TL 8233 (USD 2200) per treated patient, treatment with anidulafungin was estimated to save an additional 0.58 life-years, with an incremental cost-effectiveness ratio of TL 15 410 (USD 4118) per life-years saved. Drug acquisition cost and hospitalisation were the main cost drivers for anidulafungin and fluconazole arms respectively. The model findings were robust over a wide range of input variables except for anidulafungin drug cost. Anidulafungin appears to be a cost-effective therapy in treating IC from the Turkish hospital perspective.
URI: http://hdl.handle.net/11054/1106
Resource Link: https://www.ncbi.nlm.nih.gov/pubmed/28699297
ISSN: 0933-7407
DOI: 10.1111/myc.12651
Internal ID Number: 01079
Health Subject: ANTIFUNGAL AGENTS
CANDIDA
ANIDULAFUNGIN
FLUCONAZOLE
COST-BENEFIT ANALYSIS
CANDIDIASIS, INVASIVE
DRUG COSTS
TURKEY
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.